Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 13/20 | 1.00 |
| ▸ | GLRB | P48167 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | TAS2R46 | P59540 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Strychnine SCHEMBL93798 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL21985190 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29352583 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29362678 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL12549549 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14029424 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14117483 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL25300604 | 0.99 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL31047368 | 0.99 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL184168 | 0.99 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| WO-2007008072-A2 | CROSS-ß STRUCTURE BINDING COMPOUNDS | CROSSBETA BIOSCIENCES B.V. (NL) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | GLRA1 2447/4885GLRB 121/4885CYP3A4 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.